fzd7 crd

Fz7-21 ((Ac)-LPSDDLEFWCHVMY-NH2) is a peptide antagonist of FZD7 . It antagonises WNT3A-induced Wnt-β-catenin signalling in HEK293 expressing FZD7. Fz7-21 impairs Wnt/β-catenin signaling in HEK293 cells stimulated with exogenous WNT3A (IC50=100 nM) or transfected with a construct expressing WNT3A or WNT1. Fz7-21 also blocks WNT3A-mediated stabilization of β-catenin in mouse L cells (IC50=50 nM).

Anti-FZD7 Antibody represents a highly specialized monoclonal antibody specifically engineered to target the human Frizzled-7 receptor with exceptional binding affinity and selectivity, effectively facilitating the measurable blockade of Wnt ligand interaction across various preclinical experimental models to evaluate the inhibition of canonical beta-catenin signaling and tumor-initiating cell frequency during strictly monitored laboratory observation periods in advanced oncology research environments.

Fz7-21 TFA ((Ac)-LPSDDLEFWCHVMY-NH2 TFA), a peptide antagonist of Frizzled 7 (FZD 7) receptors, selectively binds to FZD7 CRD subclass. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively.